K= kevetrin B= brilacidin P= prurisol CTI

K= kevetrin B= brilacidin P= prurisol

CTIX Clinicals, FDA, Milestones

10/5/12 K Ph1 starts

1/24/13 K in combo w/sunitinib "first ever tumor shrinkage noted"

10/9/13 Acquired Poly assets

2/24/14 B/ABSSSI Ph2b starts

3/24/14 P Ph1 crossover study starts

8/7/14 B/ABSSSI meets Ph2b endpoints

10/13/14 B/OM Ph2 approval to commence

12/10/14 B/ABSSSI granted QIDP designation

12/10/14 P Ph2 start approved by FDA

5/22/15 K Ph1 allowed additional patient enrollment

7/20/15 K granted OrphanDrug Designation for Ovarian cancer

8/6/15 P Ph2 commences

11/23/15 K for Retinoblastoma (eye cancer) receives OrphanDrug Designation

11/25/15 B/OM granted FDA Fast Track Designation

12/1/15 K granted "Rare Pediatric Disease Designation" for Retinoblastoma

1/21/16 K receives Orphan Drug (FDA) Designation for Pancreatic Cancer
Applying for grants with research partner ?Mayo Clinic?

2/10/16 K approved for Ph2 ovarian cancer trial

2/16/16 K Ph1 trial formally concludes

2/22/16 K Ph1 early data-Increased p21 Expression in 67.5% of Evaluable
Patients

3/17/16 P ph2 last patient dosed

5/31/16 P ph2 successful trial data released

6/9/16 K ph1 "soft lock" of data

6/10/16 Rosen/scam lawsite dismissed by court.

6/15/16 B ph2 ulcerative proctitis (UB) 6 week duration overseas trial begins

7/18/16 B ph2 ulcerative proctitis (UB) 1st patient dosed reports
"amazing" results 1st week